A recent study led by researchers at the Cornell University-affiliated Boyce Thompson Institute (BTI) in collaboration with colleagues at Rutgers and Italy\u2019s San Raffaele University and Research Institute, shows that aspirin\u2019s main breakdown product, salicylic acid, blocks the protein, HMGB1, which could explain many of the drug\u2019s therapeutic properties.The findings appear Sept. 23, 2015, in the journal\u00a0Molecular Medicine.\u201cWe\u2019ve identified what we believe is a key target of aspirin\u2019s active form in the body, salicylic acid, which is responsible for some of the many therapeutic effects that aspirin has,\u201d said senior author Daniel Klessig, a professor at BTI and Cornell University. \u201cThe protein, HMGB1, is associated with many prevalent, devastating diseases, including rheumatoid arthritis, heart disease, sepsis and inflammation-associated cancers, such as colorectal cancer and mesothelioma,\u201d he said.<\/p>\n","protected":false},"author":0,"featured_media":0,"template":"","meta":{"_acf_changed":false,"footnotes":"","_links_to":"","_links_to_target":""},"class_list":["post-1031147","news","type-news","status-publish","hentry"],"acf":[],"yoast_head":"\n